Antibody Drug Conjugates Global Market Opportunities And Strategies To 2033
상품코드:1508000
리서치사:The Business Research Company
발행일:2024년 07월
페이지 정보:영문 303 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계항체약물접합체(ADC) 시장은 2018년 18억 4,794만 달러로 평가되었으며, 2023년까지 41.00% 이상의 CAGR로 성장할 것으로 예상됩니다.
지원 정책 및 신속한 승인 프로세스
지지적인 정책과 신속한 승인 절차가항체약물접합체(ADC) 시장의 성장을 가속했습니다. 지원적인 규제 정책은 암과 같은 심각한 질병에 대한항체약물접합체(ADC)와 같은 혁신적인 치료법의 개발 및 승인을 가속화합니다. 조기 승인 및 혁신 치료제 지정과 같은 신속 승인 절차는 승인 절차를 간소화하여 환자들이 ADC를 조기에 이용할 수 있도록 돕습니다. 이러한 신속한 승인 절차는 생명을 구할 수 있는 치료제가 필요한 사람들에게 적시에 제공될 수 있도록 돕습니다. 예를 들어, 2023년 3월 미국 식품의약국(FDA)은 암 치료제의 조기 승인 신청 시 임상시험에 대한 고려 사항을 요약한 지침 초안을 발표했습니다. 암 치료의 시급성 때문에 암 치료제에 자주 활용되는 이 경로는 환자에게 혁신적인 치료법에 대한 조기 접근을 제공합니다. 이번 지침은 조기 승인을 지원하는 임상시험 설계에 있어 스폰서를 지원하기 위한 것으로, 암 환자의 이익을 극대화하기 위해서는 효율적이고 질 높은 임상시험 설계가 중요하다는 점을 강조하고 있습니다. 이러한 지원 정책과 신속한 승인 절차는 지난 기간 동안항체약물접합체(ADC) 시장의 성장을 뒷받침했습니다.
목차
제1장 주요 요약
제2장 목차
제3장 표 리스트
제4장 그래프 리스트
제5장 보고서 구성
제6장 시장 특징
일반적인 시장의 정의
개요
항체약물접합체(ADC) 시장 정의와 세분화
시장 세분화 : 링커 유형별
절단형
비절단형
시장 세분화 : 제품별
Adcetris
Kadcyla
Enhertu
Polivy
Trodelvy
Padcev
기타
시장 세분화 : 용도별
조혈암
유방암
폐암
뇌종양
난소암
기타
시장 세분화 : 최종사용자별
병원 및 진료소
전문센터
기타
제7장 주요 시장 동향
제8장 항체약물접합체(ADC) 시장 : 거시경제 시나리오
COVID-19의 영향 : 항체약물접합체(ADC) 시장
우크라이나 전쟁의 영향 : 항체약물접합체(ADC) 시장
고인플레이션의 영향 : 항체약물접합체(ADC) 시장
제9장 세계 시장 규모와 성장
시장 규모
시장 성장 실적, 2018-2023
시장 성장 촉진요인, 2018-2023
시장 성장 억제요인, 2018-2023
시장 성장 예측, 2023-2028, 2033F
시장 성장 촉진요인, 2018-2023
시장 성장 억제요인, 2018-2023
제10장 세계의 항체약물접합체(ADC) 시장 : 세분화
세계의 항체약물접합체(ADC) 시장 : 링커 유형별, 실적과 예측, 2018-2023, 2028F, 2033F
세계의 항체약물접합체(ADC) 시장 : 용도별, 실적과 예측, 2018-2023, 2028F, 2033F
세계의 항체약물접합체(ADC) 시장 : 최종사용자별, 실적과 예측, 2018-2023, 2028F, 2033F
세계의 항체약물접합체(ADC) 시장 : 제품별, 실적과 예측, 2018-2023, 2028F, 2033F
제11장 항체약물접합체(ADC) 시장 : 지역 및 국가별 분석
세계의 항체약물접합체(ADC) 시장 : 지역별, 실적과 예측, 2018-2023, 2028F, 2033F
세계의 항체약물접합체(ADC) 시장 : 국가별, 실적과 예측, 2018-2023, 2028F, 2033F
제12장 아시아태평양 시장
제13장 서유럽 시장
제14장 동유럽 시장
제15장 북미 시장
제16장 남미 시장
제17장 중동 시장
제18장 아프리카 시장
제19장 경쟁 구도와 기업 개요
기업 개요
F. Hoffman-La Roche Ltd
Daiichi Sankyo Company Limited
Seagen Inc
Gilead Sciences Inc
Genmab A/S
제20장 기타 주요 기업 및 혁신 기업
Pfizer
GlaxoSmithKline plc
ADC Therapeutics SA
AstraZeneca plc
RemeGen
Astellas Pharma Inc.
ImmunoGen Inc.
Rakuten Medical
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Mersana Therapeutics Inc.
Merck Co. & KGaA
Bristol Myers Squibb Co.
Novo Nordisk A/S
Bayer AG
제21장 경쟁 벤치마킹
제22장 경쟁 대시보드
제23장 주요 인수합병(M&A)
Genmab A/S Acquired ProfoundBio Inc
Johnson & Johnson(J&J) Acquired Ambrx Biopharma Inc
AbbVie Acquired ImmunoGen, Inc
Pfizer Inc Acquired Seagen Inc
제24장 기회와 전략
새로운 기회를 제공하는 국가
새로운 기회를 제공하는 부문
성장 전략
제25장 항체약물접합체(ADC) 시장 : 결론과 제안
결론
제안
제26장 부록
LSH
영문 목차
영문목차
Antibody drug conjugates (ADCs) refer to a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. An ADC is a complex molecule that consists of an antibody linked to a biologically active drug or toxin, designed to selectively target and kill cancer cells while sparing healthy tissue.
The antibody drug conjugates market consists of sales, by entities (such as organizations, sole traders or partnerships), of antibody drug conjugates that are utilized when precision in targeting cancer cells is critical, often after other treatments have failed or in combination with other therapies to enhance efficacy. They are designed to selectively deliver chemotherapy agents to cancer cells while minimizing damage to healthy cells.
The global antibody drug conjugates market was valued at $1,847.94 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 41.00%.
Supportive Policies And Faster Approval Processes
Supportive policies and faster approval processes propelled the growth of the antibody drug conjugates market. Supportive regulatory policies accelerate the development and approval of innovative therapies such as antibody-drug conjugates (ADCs) for critical conditions such as cancer. Expedited pathways like accelerated approval and breakthrough therapy designation streamline the approval process, granting earlier access to ADCs for patients. This swift approval process ensures the timely delivery of potentially life-saving treatments to those in need. For instance, in March 2023, the Food and Drug Administration (FDA), a US-based federal agency responsible for protecting public health, released draft guidance outlining clinical trial considerations for accelerated approval applications of oncology therapeutics. This pathway, commonly utilized for oncology drugs due to the urgency of cancer treatment, offers patients early access to innovative therapies. The guidance aims to assist sponsors in designing trials that support accelerated approval, emphasizing the importance of efficient and high-quality trial design in maximizing benefits for cancer patients. Therefore, supportive policies and faster approval processes supported the growth of the antibody drug conjugates market during the historic period.
Strategic Partnerships And Collaborations Among Market Players
Major companies operating in the antibody drug conjugates market are pursuing strategic partnerships to provide comprehensive solutions and advance their capabilities. Strategic partnerships enable companies to leverage each other's strengths and resources to achieve mutual benefits and success. For example, in July 2023, BeiGene Ltd., a US-based biotechnology company, partnered with Duality Biologics, a China-based clinical-stage company. With this partnership, they aim to develop and commercialize a preclinical antibody-drug conjugate (ADC) therapy for patients with select solid tumors. The strengths of both companies will accelerate the development and commercialization of this promising ADC therapy. Further, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create antibody-drug conjugates (ADCs) for up to three cancer targets , develop and market them. The collaboration would make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Through this cooperation, candidate medications with the potential to give cancer patients and their families fresh hope would be created via the synergistic combination of molecules and platforms.
The global antibody drug conjugates market is highly concentrated, with large players dominating the market. The top ten competitors in the market made up to 99.26% of the total market in 2022.
Antibody Drug Conjugates Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global antibody drug conjugates market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for antibody drug conjugates? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider antibody drug conjugates market; and compares it with other markets.
The report covers the following chapters
Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by linker type, by product, by application and by end-user.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the antibody drug conjugates market.
Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by linker type, by product, by application and by end-user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for antibody drug conjugates providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Linker Type: Cleavable Linker; Non-Cleavable Linker
2) By Product: Kadcyla; Enhertu; Adcetris; Polivy; Trodelvy; Padcev; Other Products
3) By Application: Hematopoietic Cancers; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
4) By End User: Hospital; Clinics; Specialty Centers; Other End Users
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Daiichi Sankyo Company Limited; Seagen Inc.; Gilead Sciences Inc.; Genmab
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; antibody drug conjugates indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1 Executive Summary
1.1 Antibody Drug Conjugates - Market Attractiveness And Macro economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Antibody Drug Conjugates Market Definition And Segmentations
6.4 Market Segmentation By Linked Type
6.4.1 Cleavable Linker
6.4.2 Non-cleavable Linker
6.5 Market Segmentation By Product
6.5.1 Adcetris
6.5.2 Kadcyla
6.5.3 Enhertu
6.5.4 Polivy
6.5.5 Trodelvy
6.5.6 Padcev
6.5.7 Other Products
6.6 Market Segmentation By Application
6.6.1 Hematopoietic Cancers
6.6.2 Breast Cancer
6.6.3 Lung Cancer
6.6.4 Brain Tumor
6.6.5 Ovarian Cancer
6.6.6 Other Applications
6.7 Market Segmentation By End User
6.7.1 Hospitals And Clinics
6.7.2 Specialty Centers
6.7.3 Other End-Users
7 Major Market Trends
7.1 Strategic Partnerships And Collaborations Among Market Players
7.2 Significant Investments In R&D By Market Players
7.3 Focus On New mAb Targets For ADCs Development
8 Antibody Drug Conjugates Market - Macro Economic Scenario
8.1 COVID-19 Impact On The Antibody Drug Conjugates Market
8.2 Impact Of The War In Ukraine On The Antibody Drug Conjugates Market
8.3 Impact Of High Inflation On The Antibody Drug Conjugates Market
9 Global Market Size and Growth
9.1 Market Size
9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
